This month,Fabre-Kramer Pharmaceuticals’s antidepressant Exxua (gepirone hydrochloride) should finally receive its first regulatory approval, more than 20 years after it was initially rejected by the US Food and Drug Administration.
More than a dozen clinical trials have been conducted and the drug’s development history goes back to the mid-80s. The...